Obesity-related glomerulopathy： pathogenesis, pathologic, clinical characteristics and treatment
n light of the rapid increase in the number of obesity incidences worldwide, obesity has become an independent risk factor for chronic kidney disease. Obesity-related giomerulopathy （ORG） is characterized by glomerulomegaly in the presence or absence of focal and segmental glomerulosclerosis lesions...
Gespeichert in:
| Veröffentlicht in: | Frontiers of medicine 2017-09, Vol.11 (3), p.340-348 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 348 |
|---|---|
| container_issue | 3 |
| container_start_page | 340 |
| container_title | Frontiers of medicine |
| container_volume | 11 |
| creator | Xu, Tianhua Sheng, Zitong Yao, Li |
| description | n light of the rapid increase in the number of obesity incidences worldwide, obesity has become an independent risk factor for chronic kidney disease. Obesity-related giomerulopathy （ORG） is characterized by glomerulomegaly in the presence or absence of focal and segmental glomerulosclerosis lesions. IgM and complement 3 （C3） nonspeciflcally deposit in lesions without immune-complex-type deposits during ORG immunofluorescence. ORG-associated glomerulomegaly and focal and segmental glomerulosclerosis can superimpose on other renal pathologies. The mechanisms under ORG are complex, especially hemodynamic changes, inflammation, oxidative stress, apoptosis, and reduced functioning nephrons. These mechanisms synergize with obesity to induce end-stage renal disease. A slow increase of subnephrotic proteinuria （ 〈 3.5 g/d） is the most common clinical manifestation of ORG. Several treatment methods for ORG have been developed. Of these methods, renin-angiotensin-aldosterone system blockade and weight loss are proven effective. Targeting mitochondria may offer a novel strategy for ORG therapy. Nevertheless, more research is needed to further understand ORG. |
| doi_str_mv | 10.1007/s11684-017-0570-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1927595163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>673107874</cqvip_id><sourcerecordid>1927595163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c514t-65dc24bf4034c4f16bbf9d5b083e795f5f164009e4ba72c902efcfa3255eacf13</originalsourceid><addsrcrecordid>eNp9kUFu3SAQhq2qVROlOUA3ldVusogbwGDMsoqaNlKkbJo1wniwibB5Abx4V8lZeqdeoVh-faqyCBtm4Jt_Bv6i-IjRV4wQv4oYNy2tEOYVYhxV9ZvilCDBKkQIe3uMMT8pzmN8RHnRBnMh3hcnpOUCN017WnT3HUSb9lUApxL05eD8BGFxfqfSuP_z-7lcAz_AnLl4uWXOD1ZfltrZ2WrlSj2qoHSCYGOyOpZq7ssUQKUJ5vSheGeUi3B-2M-Kh5vvv65_Vnf3P26vv91VmmGaqob1mtDOUFRTTQ1uus6InnWorYELZlg-oggJoJ3iRAtEwGijasIYKG1wfVZcbLq74J8WiElONmpwTs3glyixIJwJhps6o19eoI9-CXOeLlM1wwJRvgrijdLBxxjAyF2wkwp7iZFcPZCbBzJ7IFcP5Kr86aC8dBP0x4p_P54BsgExX80DhP9av6LabkWjHUYI0O8CxChN8HOyEF4v_Xx4xOjn4Sm3PM7U8Boj3nJa_wUMlbF5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1935190471</pqid></control><display><type>article</type><title>Obesity-related glomerulopathy： pathogenesis, pathologic, clinical characteristics and treatment</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Xu, Tianhua ; Sheng, Zitong ; Yao, Li</creator><creatorcontrib>Xu, Tianhua ; Sheng, Zitong ; Yao, Li</creatorcontrib><description>n light of the rapid increase in the number of obesity incidences worldwide, obesity has become an independent risk factor for chronic kidney disease. Obesity-related giomerulopathy （ORG） is characterized by glomerulomegaly in the presence or absence of focal and segmental glomerulosclerosis lesions. IgM and complement 3 （C3） nonspeciflcally deposit in lesions without immune-complex-type deposits during ORG immunofluorescence. ORG-associated glomerulomegaly and focal and segmental glomerulosclerosis can superimpose on other renal pathologies. The mechanisms under ORG are complex, especially hemodynamic changes, inflammation, oxidative stress, apoptosis, and reduced functioning nephrons. These mechanisms synergize with obesity to induce end-stage renal disease. A slow increase of subnephrotic proteinuria （ 〈 3.5 g/d） is the most common clinical manifestation of ORG. Several treatment methods for ORG have been developed. Of these methods, renin-angiotensin-aldosterone system blockade and weight loss are proven effective. Targeting mitochondria may offer a novel strategy for ORG therapy. Nevertheless, more research is needed to further understand ORG.</description><identifier>ISSN: 2095-0217</identifier><identifier>EISSN: 2095-0225</identifier><identifier>DOI: 10.1007/s11684-017-0570-3</identifier><identifier>PMID: 28791668</identifier><language>eng</language><publisher>Beijing: Higher Education Press</publisher><subject>clinical characteristics ; Glomerulosclerosis, Focal Segmental - etiology ; Glomerulosclerosis, Focal Segmental - pathology ; Humans ; Kidney Diseases - diagnosis ; Kidney Diseases - etiology ; Kidney Diseases - pathology ; Kidney Diseases - therapy ; Kidney Glomerulus - pathology ; Medicine ; Medicine & Public Health ; Obesity ; Obesity - complications ; Obesity - physiopathology ; Obesity - therapy ; obesity-related glomerulopathy ; pathogenesis ; pathologic ; Review ; Risk Factors ; Weight control ; Weight Loss ; 临床特点 ; 发病机制 ; 治疗 ; 病理 ; 相关疾病 ; 肥胖 ; 肾素-血管紧张素-醛固酮系统 ; 肾脏病变</subject><ispartof>Frontiers of medicine, 2017-09, Vol.11 (3), p.340-348</ispartof><rights>Copyright reserved, 2017, Higher Education Press and Springer-Verlag Berlin Heidelberg</rights><rights>Higher Education Press and Springer-Verlag GmbH Germany 2017</rights><rights>Frontiers of Medicine is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c514t-65dc24bf4034c4f16bbf9d5b083e795f5f164009e4ba72c902efcfa3255eacf13</citedby><cites>FETCH-LOGICAL-c514t-65dc24bf4034c4f16bbf9d5b083e795f5f164009e4ba72c902efcfa3255eacf13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/71235X/71235X.jpg</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11684-017-0570-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11684-017-0570-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28791668$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Tianhua</creatorcontrib><creatorcontrib>Sheng, Zitong</creatorcontrib><creatorcontrib>Yao, Li</creatorcontrib><title>Obesity-related glomerulopathy： pathogenesis, pathologic, clinical characteristics and treatment</title><title>Frontiers of medicine</title><addtitle>Front. Med</addtitle><addtitle>Frontiers of Medicine</addtitle><description>n light of the rapid increase in the number of obesity incidences worldwide, obesity has become an independent risk factor for chronic kidney disease. Obesity-related giomerulopathy （ORG） is characterized by glomerulomegaly in the presence or absence of focal and segmental glomerulosclerosis lesions. IgM and complement 3 （C3） nonspeciflcally deposit in lesions without immune-complex-type deposits during ORG immunofluorescence. ORG-associated glomerulomegaly and focal and segmental glomerulosclerosis can superimpose on other renal pathologies. The mechanisms under ORG are complex, especially hemodynamic changes, inflammation, oxidative stress, apoptosis, and reduced functioning nephrons. These mechanisms synergize with obesity to induce end-stage renal disease. A slow increase of subnephrotic proteinuria （ 〈 3.5 g/d） is the most common clinical manifestation of ORG. Several treatment methods for ORG have been developed. Of these methods, renin-angiotensin-aldosterone system blockade and weight loss are proven effective. Targeting mitochondria may offer a novel strategy for ORG therapy. Nevertheless, more research is needed to further understand ORG.</description><subject>clinical characteristics</subject><subject>Glomerulosclerosis, Focal Segmental - etiology</subject><subject>Glomerulosclerosis, Focal Segmental - pathology</subject><subject>Humans</subject><subject>Kidney Diseases - diagnosis</subject><subject>Kidney Diseases - etiology</subject><subject>Kidney Diseases - pathology</subject><subject>Kidney Diseases - therapy</subject><subject>Kidney Glomerulus - pathology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - physiopathology</subject><subject>Obesity - therapy</subject><subject>obesity-related glomerulopathy</subject><subject>pathogenesis</subject><subject>pathologic</subject><subject>Review</subject><subject>Risk Factors</subject><subject>Weight control</subject><subject>Weight Loss</subject><subject>临床特点</subject><subject>发病机制</subject><subject>治疗</subject><subject>病理</subject><subject>相关疾病</subject><subject>肥胖</subject><subject>肾素-血管紧张素-醛固酮系统</subject><subject>肾脏病变</subject><issn>2095-0217</issn><issn>2095-0225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kUFu3SAQhq2qVROlOUA3ldVusogbwGDMsoqaNlKkbJo1wniwibB5Abx4V8lZeqdeoVh-faqyCBtm4Jt_Bv6i-IjRV4wQv4oYNy2tEOYVYhxV9ZvilCDBKkQIe3uMMT8pzmN8RHnRBnMh3hcnpOUCN017WnT3HUSb9lUApxL05eD8BGFxfqfSuP_z-7lcAz_AnLl4uWXOD1ZfltrZ2WrlSj2qoHSCYGOyOpZq7ssUQKUJ5vSheGeUi3B-2M-Kh5vvv65_Vnf3P26vv91VmmGaqob1mtDOUFRTTQ1uus6InnWorYELZlg-oggJoJ3iRAtEwGijasIYKG1wfVZcbLq74J8WiElONmpwTs3glyixIJwJhps6o19eoI9-CXOeLlM1wwJRvgrijdLBxxjAyF2wkwp7iZFcPZCbBzJ7IFcP5Kr86aC8dBP0x4p_P54BsgExX80DhP9av6LabkWjHUYI0O8CxChN8HOyEF4v_Xx4xOjn4Sm3PM7U8Boj3nJa_wUMlbF5</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Xu, Tianhua</creator><creator>Sheng, Zitong</creator><creator>Yao, Li</creator><general>Higher Education Press</general><general>Springer Nature B.V</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170901</creationdate><title>Obesity-related glomerulopathy： pathogenesis, pathologic, clinical characteristics and treatment</title><author>Xu, Tianhua ; Sheng, Zitong ; Yao, Li</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c514t-65dc24bf4034c4f16bbf9d5b083e795f5f164009e4ba72c902efcfa3255eacf13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>clinical characteristics</topic><topic>Glomerulosclerosis, Focal Segmental - etiology</topic><topic>Glomerulosclerosis, Focal Segmental - pathology</topic><topic>Humans</topic><topic>Kidney Diseases - diagnosis</topic><topic>Kidney Diseases - etiology</topic><topic>Kidney Diseases - pathology</topic><topic>Kidney Diseases - therapy</topic><topic>Kidney Glomerulus - pathology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - physiopathology</topic><topic>Obesity - therapy</topic><topic>obesity-related glomerulopathy</topic><topic>pathogenesis</topic><topic>pathologic</topic><topic>Review</topic><topic>Risk Factors</topic><topic>Weight control</topic><topic>Weight Loss</topic><topic>临床特点</topic><topic>发病机制</topic><topic>治疗</topic><topic>病理</topic><topic>相关疾病</topic><topic>肥胖</topic><topic>肾素-血管紧张素-醛固酮系统</topic><topic>肾脏病变</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Tianhua</creatorcontrib><creatorcontrib>Sheng, Zitong</creatorcontrib><creatorcontrib>Yao, Li</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Frontiers of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Tianhua</au><au>Sheng, Zitong</au><au>Yao, Li</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Obesity-related glomerulopathy： pathogenesis, pathologic, clinical characteristics and treatment</atitle><jtitle>Frontiers of medicine</jtitle><stitle>Front. Med</stitle><addtitle>Frontiers of Medicine</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>11</volume><issue>3</issue><spage>340</spage><epage>348</epage><pages>340-348</pages><issn>2095-0217</issn><eissn>2095-0225</eissn><abstract>n light of the rapid increase in the number of obesity incidences worldwide, obesity has become an independent risk factor for chronic kidney disease. Obesity-related giomerulopathy （ORG） is characterized by glomerulomegaly in the presence or absence of focal and segmental glomerulosclerosis lesions. IgM and complement 3 （C3） nonspeciflcally deposit in lesions without immune-complex-type deposits during ORG immunofluorescence. ORG-associated glomerulomegaly and focal and segmental glomerulosclerosis can superimpose on other renal pathologies. The mechanisms under ORG are complex, especially hemodynamic changes, inflammation, oxidative stress, apoptosis, and reduced functioning nephrons. These mechanisms synergize with obesity to induce end-stage renal disease. A slow increase of subnephrotic proteinuria （ 〈 3.5 g/d） is the most common clinical manifestation of ORG. Several treatment methods for ORG have been developed. Of these methods, renin-angiotensin-aldosterone system blockade and weight loss are proven effective. Targeting mitochondria may offer a novel strategy for ORG therapy. Nevertheless, more research is needed to further understand ORG.</abstract><cop>Beijing</cop><pub>Higher Education Press</pub><pmid>28791668</pmid><doi>10.1007/s11684-017-0570-3</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2095-0217 |
| ispartof | Frontiers of medicine, 2017-09, Vol.11 (3), p.340-348 |
| issn | 2095-0217 2095-0225 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1927595163 |
| source | MEDLINE; SpringerNature Journals |
| subjects | clinical characteristics Glomerulosclerosis, Focal Segmental - etiology Glomerulosclerosis, Focal Segmental - pathology Humans Kidney Diseases - diagnosis Kidney Diseases - etiology Kidney Diseases - pathology Kidney Diseases - therapy Kidney Glomerulus - pathology Medicine Medicine & Public Health Obesity Obesity - complications Obesity - physiopathology Obesity - therapy obesity-related glomerulopathy pathogenesis pathologic Review Risk Factors Weight control Weight Loss 临床特点 发病机制 治疗 病理 相关疾病 肥胖 肾素-血管紧张素-醛固酮系统 肾脏病变 |
| title | Obesity-related glomerulopathy： pathogenesis, pathologic, clinical characteristics and treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T17%3A03%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Obesity-related%20glomerulopathy%EF%BC%9A%20pathogenesis,%20pathologic,%20clinical%20characteristics%20and%20treatment&rft.jtitle=Frontiers%20of%20medicine&rft.au=Xu,%20Tianhua&rft.date=2017-09-01&rft.volume=11&rft.issue=3&rft.spage=340&rft.epage=348&rft.pages=340-348&rft.issn=2095-0217&rft.eissn=2095-0225&rft_id=info:doi/10.1007/s11684-017-0570-3&rft_dat=%3Cproquest_cross%3E1927595163%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1935190471&rft_id=info:pmid/28791668&rft_cqvip_id=673107874&rfr_iscdi=true |